Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4h ago
0mins
Should l Buy NSRX?
Source: seekingalpha
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NSRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NSRX
Wall Street analysts forecast NSRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSRX is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.400
Low
19.00
Averages
19.00
High
19.00
Current: 5.400
Low
19.00
Averages
19.00
High
19.00
About NSRX
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nasus Pharma Secures $15 Million in Private Placement Financing
- Financing Size: Nasus Pharma has entered into a securities purchase agreement for a private placement of $15 million, expected to close on February 12, 2026, with proceeds aimed at advancing the clinical development of NS002 and other pipeline products.
- Share Issuance Details: The private placement will issue 2,695,425 ordinary shares and the same number of warrants, priced at $5.565 per share, with warrants exercisable at $6.53, reflecting investor confidence in the company's growth potential.
- Market Reaction: The placement price exceeds Nasus Pharma's recent closing price, indicating a positive outlook from investors regarding the company's future market performance, which may have a favorable impact on its stock price.
- Strategic Use: The company intends to use the net proceeds to advance pivotal clinical studies for NS002, initiate first-in-human trials for other products, and for general corporate purposes, demonstrating its ongoing commitment to innovative drug development.
See More
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
See More
Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO
New Executive Appointment: Nasus Pharma has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical sectors.
Role and Responsibilities: Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company progresses its intranasal therapeutics pipeline.
Company's Focus: Nasus Pharma is developing innovative intranasal products, including a needle-free alternative to Epinephrine autoinjectors for anaphylaxis, utilizing proprietary powder-based intranasal technology for rapid drug delivery.
Leadership Confidence: The company's leadership expresses confidence in Mr. Rubin's expertise to enhance financial and operational capabilities, supporting the advancement of clinical programs and long-term growth.
See More
Nasus Pharma Secures $15 Million in Private Placement Financing
- Financing Size: Nasus Pharma has entered into a securities purchase agreement for a private placement of $15 million, expected to close on February 12, 2026, with proceeds aimed at advancing the clinical development of NS002 and other pipeline products.
- Share Issuance Details: The private placement will issue 2,695,425 ordinary shares and the same number of warrants, priced at $5.565 per share, with warrants exercisable at $6.53, reflecting investor confidence in the company's growth potential.
- Market Reaction: The placement price exceeds Nasus Pharma's recent closing price, indicating a positive outlook from investors regarding the company's future market performance, which may have a favorable impact on its stock price.
- Strategic Use: The company intends to use the net proceeds to advance pivotal clinical studies for NS002, initiate first-in-human trials for other products, and for general corporate purposes, demonstrating its ongoing commitment to innovative drug development.
See More
Nasus Pharma Prices $15M Private Placement to Fund Clinical Trials
- Private Placement Size: Nasus Pharma successfully priced a $15 million private placement involving 2,695,425 ordinary shares and matching warrants at $5.565 per unit, reflecting market confidence in its future prospects as it exceeds the prior NYSE American close.
- Warrant Terms: The warrants have an exercise price of $6.53, are immediately exercisable, and will expire either two years from issuance or 30 trading days after the NS002 pivotal study results, providing investors with a potential profit opportunity.
- Clear Use of Proceeds: The net proceeds from this financing will fund the advancement of NS002's pivotal trial, first-in-human studies for other intranasal products, and general corporate needs, ensuring ongoing investment in research and operations.
- Investor Participation: Both new and existing investors, including board members, participated in this private placement, demonstrating trust and support for Nasus Pharma's future development, with the placement expected to close on or about February 12, 2026.
See More
Nasus Pharma Enhances Leadership by Appointing Eyal Rubin as Executive Vice President and CFO
New Executive Appointment: Nasus Pharma has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical sectors.
Role and Responsibilities: Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company progresses its intranasal therapeutics pipeline.
Company's Focus: Nasus Pharma is developing innovative intranasal products, including a needle-free alternative to Epinephrine autoinjectors for anaphylaxis, utilizing proprietary powder-based intranasal technology for rapid drug delivery.
Leadership Confidence: The company's leadership expresses confidence in Mr. Rubin's expertise to enhance financial and operational capabilities, supporting the advancement of clinical programs and long-term growth.
See More
